Auto Stem Cell Transplant for Lymphoma Patients
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
AgeUp to 75
SponsorMasonic Cancer Center, University of Minnesota
About this trial
This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.
Eligibility criteria
Qualifiers
Eligible Diseases
Non-Hodgkin's Lymphoma (NHL)
Patients with chemo-sensitive histologically confirmed NHL will be eligible for this treatment protocol contingent on histologic sub-classification.
Patients in partial or complete remission following cell therapy will also be eligible.
Disqualifiers
Pregnant or breastfeeding: Females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy
Eligible for any higher priority transplant protocols
Chemotherapy resistant disease
Unrelated active infection
Trial design
Treatments tested in this trial
- Etoposide
- BCNU
- AraC
- Melphalan
- Peripheral blood stem cell transplantation
- G-CSF
- Cyclophosphamide
- Total Body Irradiation
Treatment groups
150 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov